CXCL12 and glioblastoma: In conclusion, our results emphasize the need for further characterization of the GBM microenvironment to identify additional druggable targets and provide a rationale to intensify the in-depth investigation of a potential biomarker-stratified treatment of GBM with RT and CXCL12-directed therapy.